Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > MAPP > Summary

MAP Pharmaceuticals, Inc.
(MAPP)

14.98USD   Down 0.05 (0.33%)   
At 2:30AM IST
 MAP Pharmaceuticals, Inc. (NGM:MAPP) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Last Trade: 14.98USD
Trade Time:2:30AM IST
Change:Down 0.05 (0.33%) 
Prev Close:15.03
Open:15.21
Bid:14.57 x 100
Ask:15.85 x 100
1y Target Est:16.20
Day's Range:14.89 - 15.21
52wk Range:1.57 - 16.80
Volume:110,074
Avg Vol (3m):207,508
Market Cap:366.92M
P/E (ttm):N/A
EPS (ttm):-0.82
Div & Yield:N/A (N/A%)
Add MAPP to Portfolio   Download Data

HEADLINES

 
•MAP PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers - EDGAR Online  - Fri, Feb 5
•Best Performing Stocks Year to Date - Seeking Alpha  - Tue, Feb 2
•FDA Clears the Way for MAP Pharmaceuticals - Seeking Alpha  - Sat, Jan 16
•Healthcare Stock Alert for MAP Pharmaceuticals Inc. issued by Beacon Equity - GlobeNewswire  - Wed, Jan 13
•Map Pharmaceuticals Shares on Good News for Migraine Drug - Fox Business  - Tue, Jan 12
•[$$] MedCath Moves Up; Berry Slips 5.4% - The Wall Street Journal Online  - Tue, Jan 12
•McMoRan Exploration, MAP Pharmaceuticals: Biggest Price Gainers (MMR, MAPP) - The Wall Street Journal Online  - Tue, Jan 12
•Map Pharmaceuticals Inc and K Tron International Lead Small-Cap Percentage Gainers - SmallCapInvestor.com  - Tue, Jan 12
•Biotech Stocks: MAP, Inhibitex, Vivus lead drug stocks north - MarketWatch  - Tue, Jan 12
•MAP Pharma says FDA doesn't need new Levadex study - AP  - Tue, Jan 12
•UPDATE - MAP says FDA waives second trial for migraine drug - Reuters  - Mon, Jan 11
•Biotech Stocks: MAP and Vivus lead drug stocks north - MarketWatch  - Mon, Jan 11
» More Headlines for MAPP...

ANALYST

 
EPS Est (next year) (Dec-09) :-0.27
EPS Est (in 2 years) (Dec-10) :-1.89
Avg Rec (current)*:1.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States.

» Full Company Profile